An experimental RSV vaccine for pregnant women from Pfizer is effective at protecting newborns against severe illness for at least six months, the company said in a press release Tuesday.
In a phase 3 study, the Pfizer vaccine was about 82% effective against severe illness from respiratory syncytial virus, or RSV, in the first 90 days of life in babies born to vaccinated women, according to the company. The vaccine was also about 70% effective against severe infections through the first six months of life.
Protection against any RSV infection was lower: about 57% in the first 90 days and about 51% in the first six months.